Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Apr 22, 2025-

Results Published From TRANSCEND Study of Surmodics SurVeil DCB - Endovascular Today

April 22, 2025—Surmodics, Inc. announced the publication of results from the TRANSCEND clinical trial. The global randomized study demonstrated that the company’s SurVeil drug-coated balloon (DCB) is noninferior to the In.Pact Admiral DCB (Medtronic) for safety and efficacy in patients with femoropopliteal arterial disease, while using a substantially lower drug dose than the In.Pact Admiral device, stated the company. The findings were publishe…